Search Results

You are looking at 31 - 40 of 86 items for

  • Abstract: anti-androgenic x
  • Abstract: Birth defect x
  • Abstract: Drugs x
  • Abstract: endocrine disrupters x
Clear All Modify Search
Gavin P Vinson School of Biological and Chemical Sciences, Queen Mary University of London, London E1 4NS, UK

Search for other papers by Gavin P Vinson in
Google Scholar
PubMed
Close
and
Caroline H Brennan School of Biological and Chemical Sciences, Queen Mary University of London, London E1 4NS, UK

Search for other papers by Caroline H Brennan in
Google Scholar
PubMed
Close

Substantial evidence shows that the hypophyseal–pituitary–adrenal (HPA) axis and corticosteroids are involved in the process of addiction to a variety of agents, and the adrenal cortex has a key role. In general, plasma concentrations of cortisol (or corticosterone in rats or mice) increase on drug withdrawal in a manner that suggests correlation with the behavioural and symptomatic sequelae both in man and in experimental animals. Corticosteroid levels fall back to normal values in resumption of drug intake. The possible interactions between brain corticotrophin releasing hormone (CRH) and proopiomelanocortin (POMC) products and the systemic HPA, and additionally with the local CRH–POMC system in the adrenal gland itself, are complex. Nevertheless, the evidence increasingly suggests that all may be interlinked and that CRH in the brain and brain POMC products interact with the blood-borne HPA directly or indirectly. Corticosteroids themselves are known to affect mood profoundly and may themselves be addictive. Additionally, there is a heightened susceptibility for addicted subjects to relapse in conditions that are associated with change in HPA activity, such as in stress, or at different times of the day. Recent studies give compelling evidence that a significant part of the array of addictive symptoms is directly attributable to the secretory activity of the adrenal cortex and the actions of corticosteroids. Additionally, sex differences in addiction may also be attributable to adrenocortical function: in humans, males may be protected through higher secretion of DHEA (and DHEAS), and in rats, females may be more susceptible because of higher corticosterone secretion.

Open access
Agnieszka Kosowska Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Agnieszka Kosowska in
Google Scholar
PubMed
Close
,
Enrique Gallego-Colon Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Enrique Gallego-Colon in
Google Scholar
PubMed
Close
,
Wojciech Garczorz Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Wojciech Garczorz in
Google Scholar
PubMed
Close
,
Agnieszka Kłych-Ratuszny Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Agnieszka Kłych-Ratuszny in
Google Scholar
PubMed
Close
,
Mohammad Reza F Aghdam Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Mohammad Reza F Aghdam in
Google Scholar
PubMed
Close
,
Michał Woz´niak Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Michał Woz´niak in
Google Scholar
PubMed
Close
,
Andrzej Witek Department of Gynaecology and Obstetrics, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Andrzej Witek in
Google Scholar
PubMed
Close
,
Agnieszka Wróblewska-Czech Department of Gynaecology and Obstetrics, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Agnieszka Wróblewska-Czech in
Google Scholar
PubMed
Close
,
Anna Cygal Department of Gynaecology and Obstetrics, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Anna Cygal in
Google Scholar
PubMed
Close
,
Jerzy Wojnar Department of Internal Medicine and Oncological Chemotherapy, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Jerzy Wojnar in
Google Scholar
PubMed
Close
, and
Tomasz Francuz Department of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland

Search for other papers by Tomasz Francuz in
Google Scholar
PubMed
Close

Diabetes and cancer are prevalent diseases whose incidence is increasing globally. Diabetic women have a moderate risk increase in ovarian cancer, suggested to be due to an interaction between these two disorders. Furthermore, patients manifesting both diseases have associated worse prognosis, reduced survival and shorter relapse-free survival. According to current recommendations, incretin drugs such as Exenatide, a synthetic analog of Exendin-4, and Liraglutide are used as therapy for the type 2 diabetes (T2D). We studied the effects of GLP-1 and Exendin-4 on migration, apoptosis and metalloproteinase production in two human ovarian cancer cells (SKOV-3 and CAOV-3). Exendin-4 inhibited migration and promoted apoptosis through caspase 3/7 activation. Exendin-4 also modulated the expression of key metalloproteinases (MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2). Vascular endothelial cells, which contribute to the formation and progression of metastasis, were also analyzed. TNF-α-stimulated endothelial cells from iliac artery after Exendin-4 treatment showed reduced production of adhesion molecules (ICAM-1 and VCAM-1). Additionally, incretin treatment inhibited activation of apoptosis in TNF-α-stimulated endothelial cells. In the same experiment, MMPs (MMP-1 and MMP-9), which are relevant for tumor development, were also reduced. Our study demonstrated that incretin drugs may reduce cancer cell proliferation and dissemination potential, hence limiting the risk of metastasis in epithelial ovarian cancer.

Open access
Robert Rapaport Division of Pediatric Endocrinology & Diabetes, Mount Sinai Kravis Children’s Hospital and Icahn School of Medicine at Mount Sinai, New York, New York, USA

Search for other papers by Robert Rapaport in
Google Scholar
PubMed
Close
,
Jan M Wit Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands

Search for other papers by Jan M Wit in
Google Scholar
PubMed
Close
, and
Martin O Savage Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, London, UK

Search for other papers by Martin O Savage in
Google Scholar
PubMed
Close

The terms ‘idiopathic short stature’ (ISS) and ‘small for gestational age’ (SGA) were first used in the 1970s and 1980s. ISS described non-syndromic short children with undefined aetiology who did not have growth hormone (GH) deficiency, chromosomal defects, chronic illness, dysmorphic features or low birth weight. Despite originating in the pre-molecular era, ISS is still used as a diagnostic label today. The term ‘SGA’ was adopted by paediatric endocrinologists to describe children born with low birth weight and/or length, some of whom may experience lack of catch-up growth and present with short stature. GH treatment was approved by the FDA for short children born SGA in 2001, and by the EMA in 2003, and for the treatment of ISS in the US, but not Europe, in 2003. These approvals strengthened the terms ‘SGA’ and ‘ISS’ as clinical entities. While clinical and hormonal diagnostic techniques remain important, it is the emergence of genetic investigations that have led to numerous molecular discoveries in both ISS and SGA subjects. The primary message of this article is that the labels ISS and SGA are not definitive diagnoses. We propose that the three disciplines of clinical evaluation, hormonal investigation and genetic sequencing should have equal status in the hierarchy of short stature assessments and should complement each other to identify the true pathogenesis in poorly growing patients.

Open access
Xinge Tao Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Search for other papers by Xinge Tao in
Google Scholar
PubMed
Close
,
Yanbin Xue Computer Net Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Yanbin Xue in
Google Scholar
PubMed
Close
,
Rui Niu Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Search for other papers by Rui Niu in
Google Scholar
PubMed
Close
,
Wenjing Lu Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Search for other papers by Wenjing Lu in
Google Scholar
PubMed
Close
,
Huayan Yao Computer Net Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Huayan Yao in
Google Scholar
PubMed
Close
,
Chunmei He Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China

Search for other papers by Chunmei He in
Google Scholar
PubMed
Close
,
Bin Cui Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Bin Cui in
Google Scholar
PubMed
Close
, and
Changqin Liu Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
Xiamen Key Laboratory for Clinical Efficacy and Evidence-Based Research of Traditional Chinese Medicine, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China
Fujian Province Key Laboratory of Diabetes Translational Medicine, The First Affiliated Hospital of Xiamen University, School of medicine, Xiamen University, Xiamen, China

Search for other papers by Changqin Liu in
Google Scholar
PubMed
Close

Objective

The aim of this study was to compare the differences in incident population, comorbidities, and glucose-lowering drug prescriptions between newly diagnosed patients with early-onset type 2 diabetes mellitus (T2DM) and those with late-onset T2DM to provide real-world evidence for clinical practice.

Methods

This study was based on the Shanghai Hospital Link Database (SHLD). Anonymized electronic medical record (EHR) data from 2013 to 2021 were included in this study. Newly diagnosed patients with T2DM were defined as those without related diagnostic records or glucose-lowering medicine prescriptions in the past 3 years. Early-onset T2DM was defined as patients who were aged 18–40 years old at the first visit for T2DM to represent those who were born after the 1980s. And late-onset T2DM was defined as those aged 65–80 years old to represent those who were born in a relatively undeveloped period. Descriptive statistical analyses were performed to describe their incidence number, glucose-lowering drug prescriptions, and comorbidities at the first visit to the hospital between two T2DM groups.

Results

There were a total of 35,457 newly diagnosed patients with early-onset T2DM and 149,108 newly diagnosed patients with late-onset T2DM included in this study. Patients with late-onset T2DM constituted the majority and their number increased by 2.5% on average by years, while the number of patients with early-onset T2DM remained stable each year. Compared with late-onset T2DM patients, more early-onset T2DM patients had dyslipidemia at the first visit to hospitals (9.5% vs 7.7%, P < 0.01) despite their significant age differences. Patients with early-onset T2DM were more likely to use metformin (74.8% vs 46.5, P < 0.01), dipeptidyl peptidase-4 inhibitors (DDP-4i) (16.7% vs 11.2%, P < 0.01), thiazolidinediones (TZD) (14.9% vs 8.4%, P < 0.01), sodium glucose cotransporter 2 inhibitors (SGLT2-i) (0.8% vs 0.3%, P < 0.01), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) (3.7% vs 0.5%, P < 0.01) at their first visit to the hospital.

Conclusions

Different characteristics were observed between patients with early-onset T2DM and those with late-onset T2DM. Compared with patients with late-onset T2DM, those with early-onset T2DM were more prone to dyslipidemia and had novel organ-protective drugs prescribed.

Open access
Michael Ulm University of Tennessee Health Science Center, Memphis, Tennessee, USA
West Cancer Center, Memphis, Tennessee, USA

Search for other papers by Michael Ulm in
Google Scholar
PubMed
Close
,
Arvind V Ramesh White Station High School, Memphis, Tennessee, USA

Search for other papers by Arvind V Ramesh in
Google Scholar
PubMed
Close
,
Keely M McNamara Tohoku University, Miyagi, Japan

Search for other papers by Keely M McNamara in
Google Scholar
PubMed
Close
,
Suriyan Ponnusamy University of Tennessee Health Science Center, Memphis, Tennessee, USA

Search for other papers by Suriyan Ponnusamy in
Google Scholar
PubMed
Close
,
Hironobu Sasano Tohoku University, Miyagi, Japan

Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
Close
, and
Ramesh Narayanan University of Tennessee Health Science Center, Memphis, Tennessee, USA
West Cancer Center, Memphis, Tennessee, USA

Search for other papers by Ramesh Narayanan in
Google Scholar
PubMed
Close

Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.

Open access
Willem de Ronde Department of Internal Medicine, Spaarne Gasthuis, Haarlem, the Netherlands

Search for other papers by Willem de Ronde in
Google Scholar
PubMed
Close
and
Diederik L Smit Department of Internal Medicine, Spaarne Gasthuis, Haarlem, the Netherlands

Search for other papers by Diederik L Smit in
Google Scholar
PubMed
Close

This review summarizes 10 years experience with male abusers of anabolic androgenic steroids (AAS). The typical user of AAS is male, aged between 20 and 40 and lifting weights. Illegal AAS are cheap and easily obtained via internet or local suppliers. AAS are mostly used in cycles with a duration between 6 and 18 weeks. Most AAS cycles contain multiple agents, used simultaneously in a dose vastly exceeding a substitution dose. A variety of other performance and image-enhancing drugs are commonly used, including human growth hormone, thyroid hormone, tamoxifen, clomiphene citrate and human chorionic gonadotrophin. Short-term clinical and biochemical side effects are well established. Long-term side effects are uncertain, but may include heart failure, mood-and anxiety disorders, hypogonadism and subfertility. We share our views on the management of common health problems associated with AAS abuse.

Open access
Enrique Soto-Pedre Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

Search for other papers by Enrique Soto-Pedre in
Google Scholar
PubMed
Close
,
Paul J Newey Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Department of Endocrinology and Diabetes, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

Search for other papers by Paul J Newey in
Google Scholar
PubMed
Close
,
John S Bevan JJR Macleod Centre for Diabetes, Endocrinology and Metabolism (Mac-DEM), Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, UK

Search for other papers by John S Bevan in
Google Scholar
PubMed
Close
, and
Graham P Leese Division of Molecular and Clinical Medicine, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
Department of Endocrinology and Diabetes, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

Search for other papers by Graham P Leese in
Google Scholar
PubMed
Close

Purpose

High serum prolactin concentrations have been associated with adverse health outcomes in some but not all studies. This study aimed to examine the morbidity and all-cause mortality associated with hyperprolactinaemia.

Methods

A population-based matched cohort study in Tayside (Scotland, UK) from 1988 to 2014 was performed. Record-linkage technology was used to identify patients with hyperprolactinaemia that were compared to an age–sex-matched cohort of patients free of hyperprolactinaemia. The number of deaths and incident admissions with diabetes mellitus, cardiovascular disease, cancer, breast cancer, bone fractures and infectious conditions were compared by the survival analysis.

Results

Patients with hyperprolactinaemia related to pituitary tumours had no increased risk of diabetes, cardiovascular disease, bone fractures, all-cause cancer or breast cancer. Whilst no increased mortality was observed in patients with pituitary microadenomas (HR = 1.65, 95% CI: 0.79–3.44), other subgroups including those with pituitary macroadenomas and drug-induced and idiopathic hyperprolactinaemia demonstrated an increased risk of death. Individuals with drug-induced hyperprolactinaemia also demonstrated increased risks of diabetes, cardiovascular disease, infectious disease and bone fracture. However, these increased risks were not associated with the degree of serum prolactin elevation (P trend > 0.3). No increased risk of cancer was observed in any subgroup.

Conclusions

No excess morbidity was observed in patients with raised prolactin due to pituitary tumours. Although the increased morbidity and mortality associated with defined patient subgroups are unlikely to be directly related to the elevation in serum prolactin, hyperprolactinaemia might act as a biomarker for the presence of some increased disease risk in these patients.

Open access
Shruti Khare Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Shruti Khare in
Google Scholar
PubMed
Close
,
Anurag R Lila Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Close
,
Hiren Patt Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Hiren Patt in
Google Scholar
PubMed
Close
,
Chaitanya Yerawar Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Chaitanya Yerawar in
Google Scholar
PubMed
Close
,
Manjunath Goroshi Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed
Close
,
Tushar Bandgar Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Close
, and
Nalini S Shah Department of Endocrinology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India

Search for other papers by Nalini S Shah in
Google Scholar
PubMed
Close

Macroprolactinomas are the most common functional pituitary tumours. Hypotheses proposed to explain predominance of large tumours in males are: i) diagnostic delay, as hyperprolactinaemia remains under recognised in males and ii) gender-specific difference in tumour proliferation indices. Our study objectives are to compare gender differences in clinical, biochemical, radiological features, management outcomes and cabergoline responsiveness in macroprolactinomas. Drug resistance was defined as failure to achieve prolactin normalisation and >50% reduction in tumour volume with cabergoline (3.5 mg/week dose for minimum 6 months duration). The baseline characteristics of 100 patients (56 females and 44 males) with macroprolactinoma were analysed. Drug responsiveness was analysed in 88 treatment naive patients, excluding 12 post-primary trans-sphenoidal surgery cases. We found that females (30.29±10.39 years) presented at younger mean age than males (35.23±9.91 years) (P<0.01). The most common presenting symptom was hypogonadism (oligo-amenorrhoea/infertility) in females (96.15%) and symptoms of mass effect (headache and visual field defects) in males (93.18%). Baseline mean prolactin levels were significantly lower in females (3094.36±6863.01 ng/ml) than males (7927.07±16 748.1 ng/ml) (P<0.001). Maximal tumour dimension in females (2.49±1.48 cm) was smaller than males (3.93±1.53 cm) (P<0.001). In 88 treatment naïve patients, 27.77% females and 35.29% males had resistant tumours (P=0.48). On subgrouping as per maximum tumour dimension (1.1–2 cm, 2.1–4 cm and >4 cm), gender difference in response rate was insignificant. In conclusion, macroprolactinomas are equally prevalent in both sexes. Macroprolactinomas in males predominantly present with symptoms of mass effects, as against females who present with symptoms of hypogonadism. Males harbor larger tumours but are equally cabergoline responsive as those in females.

Open access
Eva Olga Melin Department of Clinical Sciences, Endocrinology and Diabetes, Lund University, Faculty of Medicine, Lund, Sweden
Department of Research and Development, Region Kronoberg, Växjö, Sweden
Region Kronoberg, Primary Care, Växjö, Sweden

Search for other papers by Eva Olga Melin in
Google Scholar
PubMed
Close
,
Jonatan Dereke Department of Clinical Sciences Lund, Lund University, Faculty of Medicine, Diabetes Research Laboratory, Lund, Sweden

Search for other papers by Jonatan Dereke in
Google Scholar
PubMed
Close
,
Maria Thunander Department of Clinical Sciences, Endocrinology and Diabetes, Lund University, Faculty of Medicine, Lund, Sweden
Department of Research and Development, Region Kronoberg, Växjö, Sweden
Department of Internal Medicine, Endocrinology and Diabetes, Central Hospital, Växjö, Sweden

Search for other papers by Maria Thunander in
Google Scholar
PubMed
Close
, and
Magnus Hillman Department of Clinical Sciences Lund, Lund University, Faculty of Medicine, Diabetes Research Laboratory, Lund, Sweden

Search for other papers by Magnus Hillman in
Google Scholar
PubMed
Close

Objective

Neuroinflammatory responses are implicated in depression. The aim was to explore whether depression in patients with type 1 diabetes (T1D) was associated with high circulating galectin-3, controlling for metabolic variables, s-creatinine, life style factors, medication and cardiovascular complications.

Design

Cross-sectional.

Methods

Participants were T1D patients (n = 283, 56% men, age 18–59 years, diabetes duration ≥1 year). Depression was assessed by Hospital Anxiety and Depression Scale-depression subscale. Blood samples, anthropometrics and blood pressure were collected, and supplemented with data from medical records and the Swedish National Diabetes Registry. Galectin-3 ≥2.562 µg/l, corresponding to the 85th percentile, was defined as high galectin-3.

Results

Median (quartile1, quartile3) galectin-3 (µg/l) was 1.3 (0.8, 2.9) for the 30 depressed patients, and 0.9 (0.5, 1.6) for the 253 non-depressed, P = 0.009. Depression was associated with high galectin-3 in all the 283 patients (adjusted odds ratio (AOR) 3.5), in the 161 men (AOR 3.4), and in the 122 women (AOR 3.9). HbA1c, s-lipids, s-creatinine, blood pressure, obesity, smoking, physical inactivity, cardiovascular complications and drugs (antihypertensive, lipid lowering, oral antidiabetic drugs and antidepressants) were not associated with high galectin-3.

Conclusions

This is the first study to show an association between depression and galectin-3. Depression was the only explored parameter associated with high circulating galectin-3 levels in 283 T1D patients. High galectin-3 levels might contribute to the increased risk for Alzheimer’s disease, cardiovascular and all-cause mortality observed in persons with depression. Potentially, in the future, treatment targeting galactin-3 might improve the prognosis for patients with high galectin-3 levels.

Open access
Metin Guclu Health Sciences University, Bursa Yuksek Ihtisas Education and Training Hospital, Department of Endocrinology and Metabolism, Bursa, Turkey

Search for other papers by Metin Guclu in
Google Scholar
PubMed
Close
,
Sinem Kiyici Health Sciences University, Bursa Yuksek Ihtisas Education and Training Hospital, Department of Endocrinology and Metabolism, Bursa, Turkey

Search for other papers by Sinem Kiyici in
Google Scholar
PubMed
Close
,
Zulfiye Gul Department of Pharmacology, Uludag University Medical Faculty, Bursa, Turkey

Search for other papers by Zulfiye Gul in
Google Scholar
PubMed
Close
, and
Sinan Cavun Department of Pharmacology, Uludag University Medical Faculty, Bursa, Turkey

Search for other papers by Sinan Cavun in
Google Scholar
PubMed
Close

Aim

In the present study, we investigated the long-term effects of exenatide treatment on serum fasting ghrelin levels in patients with type 2 diabetes mellitus.

Methods

Type 2 diabetic patients, who were using metformin with and without the other antihyperglycemic drugs on a stable dose for at least 3 months, were enrolled in the study. BMI>35 kg/m2 and HbA1c>7.0% were the additional inclusion criteria. Oral antihyperglycemic drugs, other than metformin, were stopped, and metformin treatment was continued at 2000 mg per day. Exenatide treatment was initiated at 5 µg per dose subcutaneously (sc) twice daily, and after one month, the dose of exenatide was increased to 10 µg twice daily. Changes in anthropometric variables, glycemic control, lipid parameters and total ghrelin levels were evaluated at baseline and following 12 weeks of treatment.

Results

Thirty-eight patients (male/female = 7/31) entered the study. The mean age of patients was 50.5 ± 8.8 years with a mean diabetes duration of 8.5 ± 4.9 years. The mean BMI was 41.6 ± 6.3 kg/m2 and the mean HbA1c of patients was 8.9 ± 1.4%. The mean change in the weight of patients was −5.6 kg and the percentage change in weight was −5.2 ± 3.7% following 12 weeks of treatment. BMI, fasting plasma glucose and HbA1c levels of patients were decreased significantly (P < 0.001 and P < 0.001; respectively), while there was no change in lipid parameters. Serum fasting ghrelin levels were significantly suppressed following 12 weeks of exenatide treatment compared with baseline values (328.4 ± 166.8 vs 245.3 ± 164.8 pg/mL) (P = 0.024).

Conclusion

These results suggest that the effects of exenatide on weight loss may be related with the suppression of serum fasting ghrelin levels, which is an orexigenic peptide.

Open access